Autres langues Lupin Limited

Actions

LUPIN

INE326A01037

Marché Fermé - Bombay S.E. Autres places de cotation 06:18:28 11/06/2024			Varia. 5j.	Varia. 1 janv.
1 622 ^INR	-0,84 %		+3,83 %	+22,68 %

05/06	Lupin Arm acquiert deux marques de Sanofi en Europe et au Canada	MT
30/05	Les ventes à l'exportation de produits pharmaceutiques de l'Inde devraient croître plus rapidement cette année, selon un organisme commercial	RE

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lupin : June 5, 2024 Lupin Completes Acquisition of two Brands from Sanofi in Europe and Canada	05/06
Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada	05/06
Lupin : June 3, 2024 Lupin Receives Tentative Approval from U.S. FDA for Letermovir Tablets	03/06
Lupin : June 3, 2024 Lupin Launches Doxycycline for Injection USP in the United States	03/06
India's pharma export sales to grow faster this year, trade body says	30/05
Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research	27/05
Lupin Gets Six Observations from US FDA After Somerset Unit Inspection	20/05
U.S. FDA Concludes a Pre Approval Inspection at Lupin's Somerset, New Jersey Manufacturing Facility	19/05
Lupin : May 16, 2024 Lupin Receives Approval from U.S. FDA for Midostaurin Capsules	16/05
Lupin : May 15, 2024 Lupin Achieves Significant Milestone with ISO 14001 and ISO 45001 Certification Across All its Indian Manufacturing Sites, R&D Center and Corporate Office	15/05
Lupin Relaunches Mirabegron ER Tablets in US	13/05
Lupin : May 9, 2024 Jeffrey Kindler and Alfonso Zulueta Join Lupin Board as Independent Directors	09/05
Lupin Limited Announces Board Appointments	09/05
Lupin's Consolidated Profit Climbs in Fiscal Q4; Shares Dip 4%	07/05
Indian drugmaker Lupin misses quarterly profit estimates as costs rise	06/05
Lupin : May 6, 2024 Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP	06/05
Lupin Limited Board Recommends Dividend for the Year Ended March 31, 2024	06/05
Lupin Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	06/05
Lupin Limited Reports Earnings Results for the Full Year Ended March 31, 2024	06/05
Lupin Limited Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP	06/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lupin Limited

Actions

LUPIN

INE326A01037

Autres langues

Filtres